Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer

• Published in: Phytomedicine (Stuttgart) 2024-06, Vol.128, p.155431-155431, Article 155431
• Main Authors: Zhang, Yi-Zhong, Lai, Huan-Ling, Huang, Chen, Jiang, Ze-Bo, Yan, Hao-Xin, Wang, Xuan-Run, Xie, Chun, Huang, Ju-Min, Ren, Wen-Kang, Li, Jia-Xin, Zhai, Zhi-Ran, Yao, Xiao-Jun, Wu, Qi-Biao, Leung, Elaine Lai-Han
• Format: Article
• Language: English
• Subjects: A549 Cells; Abietanes - pharmacology; Animals; Antineoplastic Agents, Phytogenic - pharmacology; B7-H1 Antigen - metabolism; Carcinoma, Non-Small-Cell Lung - drug therapy; Cell Line, Tumor; Endoplasmic Reticulum Stress - drug effects; ER stress; Female; Humans; Immunotherapy - methods; JNK; JNK Mitogen-Activated Protein Kinases - metabolism; Lung Neoplasms - drug therapy; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NFAT2; NFATC Transcription Factors - metabolism; NSCLC; PD-L1; Programmed Cell Death 1 Receptor; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc - metabolism; Tanshinone IIA; Xenograft Model Antitumor Assays
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2024.155431

Non-small cell lung cancer (NSCLC) remains at the forefront of new cancer cases, and there is an urgent need to find new treatments or improve the efficacy of existing therapies. In addition to the application in the field of cerebrovascular diseases, recent studies have revealed that tanshinone IIA (Tan IIA) has anticancer activity in a variety of cancers. To investigate the potential anticancer mechanism of Tan IIA and its impact on immunotherapy in NSCLC. Cytotoxicity and colony formation assays were used to detect the Tan IIA inhibitory effect on NSCLC cells. This research clarified the mechanisms of Tan IIA in anti-tumor and programmed death-ligand 1 (PD-L1) regulation by using flow cytometry, transient transfection, western blotting and immunohistochemistry (IHC) methods. Besides, IHC was also used to analyze the nuclear factor of activated T cells 1 (NFAT2) expression in NSCLC clinical samples. Two animal models including xenograft mouse model and Lewis lung cancer model were used for evaluating tumor suppressive efficacy of Tan IIA. We also tested the efficacy of Tan IIA combined with programmed cell death protein 1 (PD-1) inhibitors in Lewis lung cancer model. Tan IIA exhibited good NSCLC inhibitory effect which was accompanied by endoplasmic reticulum (ER) stress response and increasing Ca2+ levels. Moreover, Tan IIA could suppress the NFAT2/ Myc proto oncogene protein (c-Myc) signaling, and it also was able to control the Jun Proto-Oncogene(c-Jun)/PD-L1 axis in NSCLC cells through the c-Jun N-terminal kinase (JNK) pathway. High NFAT2 levels were potential factors for poor prognosis in NSCLC patients. Finally, animal experiments data showed a stronger immune activation phenotype, when we performed treatment of Tan IIA combined with PD-1 monoclonal antibody. The findings of our research suggested a novel mechanism for Tan IIA to inhibit NSCLC, which could exert anti-cancer effects through the JNK/NFAT2/c-Myc pathway. Furthermore, Tan IIA could regulate tumor PD-L1 levels and has the potential to improve the efficacy of PD-1 inhibitors. [Display omitted]